The Terasaki Institute for Biomedical Innovation’s company, OnVagus, has received approval to begin the first human trial of its noninvasive nerve-stimulation device for patients experiencing cancer-related wasting. Cachexia, a severe wasting syndrome characterized by unintentional weight and muscle loss, affects many patients with advanced cancer and cannot be reversed through nutrition alone. Up to half of all cancer deaths are attributable to cachexia, and no **FDA**-approved therapies exist, representing a significant unmet need. The OnVagus device delivers noninvasive electrical stimulation through the skin to modulate the vagus nerve, a major nerve pathway connecting the brain to organs including the gut and liver. This approach, established through a preclinical study published in Cell, is described as the first transcutaneous vagal block device designed for human use.
The initial trial will commence with a safety lead-in trial involving 10 pancreatic cancer patients at MD Anderson Cancer Center, with the first patient expected to enroll in October. The eight-week study will primarily assess the device’s safety and usability, alongside secondary measures including preliminary relief of cachectic symptoms and biomarkers such as liver function. Exploratory measures will also be taken regarding progression-free and overall survival. The trial is supported by funding from the National Cancer Institute’s **SBIR** program, an **NIH** R01 award to MD Anderson, the American Cancer Society, and BrightEdge. If the initial safety and usability results are positive, a year-long, 120-patient randomized, double-blind trial will be launched. This study will compare the active device to a sham device, with the primary outcome being a composite of extended time on chemotherapy and reduced cachectic weight loss. Secondary measures will include activity, mood, and muscle retention, alongside assessments of liver function and neurotransmitter levels. The work reflects the Terasaki Institute’s mission to move practical, translational technologies from the laboratory into real-world patient care, and is being overseen by **MD** experts.